Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis

Kimberly Cipko; Alice Kizny Gordon; Suman Adhikari; Pamela Konecny

doi:10.1016/j.ijid.2021.06.035

Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis

Int J Infect Dis. 2021 Aug:109:108-111. doi: 10.1016/j.ijid.2021.06.035. Epub 2021 Jun 23.

Authors

Kimberly Cipko¹, Alice Kizny Gordon², Suman Adhikari³, Pamela Konecny⁴

Affiliations

¹ Department of Infectious Diseases, Immunology and Sexual Health, St George Hospital, Sydney, New South Wales, Australia; Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia. Electronic address: kimberly.cipko@health.nsw.gov.au.
² Department of Microbiology, New South Wales Health Pathology, St George Hospital, New South Wales, Australia; St George and Sutherland Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
³ St George and Sutherland Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; Department of Pharmacy, St George Hospital, Sydney, New South Wales, Australia.
⁴ Department of Infectious Diseases, Immunology and Sexual Health, St George Hospital, Sydney, New South Wales, Australia; St George and Sutherland Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.

PMID: 34157388
DOI: 10.1016/j.ijid.2021.06.035

Abstract

Infections with extensively drug-resistant Acinetobacter baumannii (XDRAB) have limited therapeutic options. We report successful salvage treatment of XDRAB and Pseudomonas aeruginosa-infected retained spinal hardware with cefiderocol, despite the development of reversible acute interstitial nephritis after 32 days of treatment.

Keywords: Acute interstitial nephritis; Biofilm; Cefiderocol; Extensively drug-resistant Acinetobacter baumannii (XDRAB); MDR Gram-negative; Spinal hardware infection; Surgical site infection.

Publication types

Case Reports

MeSH terms

Acinetobacter baumannii*
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Cefiderocol
Cephalosporins / therapeutic use
Drug Resistance, Multiple, Bacterial
Humans
Microbial Sensitivity Tests
Nephritis, Interstitial* / drug therapy
Pharmaceutical Preparations*
Pseudomonas aeruginosa

Substances

Anti-Bacterial Agents
Cephalosporins
Pharmaceutical Preparations